Interface Biologics Announces Series B Financing Round with DSM and BDC Capital

Toronto, ON, Canada, January 13, 2015 -- Interface Biologics Inc. (IBI), an innovative developer of biomedical-polymer technologies which improve the safety and effectiveness of medical devices, is pleased to announce the completion of a Series B financing round led by DSM Venturing and existing investor, BDC Capital. “Interface Biologics is a great strategic and a financial investment for DSM” remarked Pieter Wolters, Managing Director of DSM Venturing, the corporate venturing arm of Royal DSM, a €10 billion global science-based company active in health, nutrition and materials. “The fit with DSM’s activities in Biomedical offers significant opportunities to create incremental value.”

“BDC Capital has been an early and active investor in Interface Biologics since 2004” stated Dion Madsen, Senior Managing Partner in the Healthcare Venture Fund at BDC, “We believe the company is at the right stage to capitalize on the opportunity to work with a major strategic investor and accelerate the commercialization of its polymer technologies and the products that they enable.”

“We’re very pleased to have completed this Series B financing”, commented Tom Reeves, President & CEO of Interface Biologics. “Having a strategic investor like DSM in combination with BDC underscores both IBI’s success to date and the confidence that our investors have in our future. We look forward to working with DSM as we continue the commercial development of our surface modifying macromolecules and our drug delivery polymer technology platforms.”

Click here to view the full news release.

SERNOVA PROVIDES CORPORATE UPDATE

ADVANCES MADE IN CELL POUCH(TM) CLINICAL DEVELOPMENT AND POSITIVE OUTLOOK FOR COMPANY’S NEW THERAPEUTIC CELL TECHNOLOGIES Source: Sernova Corp

FOR RELEASE November 10th, 2014, 6:00 a.m. EST

LONDON, ONTARIO--(Marketwire – November 10th, 2014) - Sernova Corp. (TSX-V: SVA), a clinical stage company developing cell therapy technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and hemophilia, today provides a corporate update, summarizing advances made in the clinical development of its Cell Pouch(TM) over the past 12 months and the application of its technologies to new disease indications.

Cell Pouch(TM) Clinical Initiatives

The clinical assessment of the Cell Pouch(TM) in brittle diabetic patients with hypoglycemia unawareness who have received an islet transplant has shown in a small cohort of patients in interim analysis that the Cell Pouch(TM) is biocompatible and safe following implant and transplant. Safety is the primary endpoint of the study. Initial data from the study have shown the following three important findings:

• First, biocompatibility and a positive safety profile of the Cell Pouch(TM) have been shown in the first cohort of patients.

• Second, the islets within the Cell Pouch(TM), as shown by histological analysis, are well-vascularized, living within a natural tissue matrix and are able to make insulin, glucagon and somatostatin, key hormones in the control of blood glucose levels. We believe such revascularization of islets and islet metabolic function within an implantable medical device for therapeutic cells in humans in this patient population is a first in the regenerative medicine field.

• Third, these positive developments of the study suggest that Sernova’s Cell Pouch(TM) may form a suitable environment for the survival and function of multiple types of therapeutic cells including human stem cells which can represent a virtually unlimited supply of cells for treating disease.

“Sernova has achieved a major milestone with its first-in-human testing”, remarked Dr. James Shapiro, Principal Investigator for the diabetes study. “Our respective scientific teams are moving ahead to accelerate the pace of innovation, and believe the Cell Pouch(TM) is a highly promising vehicle for transplantation of future stem cell therapies”.

With the encouraging pre-clinical and interim clinical results, Sernova maintains its longer term strategy and objective to achieve a complete solution for treatment of insulin-dependent diabetes, including access to an unlimited supply of insulin producing tissue such as that developed from stem cell technologies, and protection from immune system attack using local immune protection technologies within the pre-vascularized Cell Pouch(TM).

Research and Development Collaboration with Dr. Shapiro

In an independent pre-clinical study, it has been shown that the Cell Pouch(TM) provided insulin independence for 100 days in a small animal model of diabetes using a marginal (minimal) transplanted islet mass. The encouraging results of this study will be released in more detail upon acceptance for publication in a peer reviewed medical journal.

Hemophilia Collaboration with Medicyte GmbH

The research and development teams at Medicyte and Sernova are continuing to work closely in the development of a product to treat Hemophilia A patients. This product involves taking a small blood sample from the patient, correcting the genetic defect in isolated cells and then using Medicyte’s upcyte® technology to expand the cell numbers for placement into the Cell Pouch(TM) for release of Factor VIII. The teams are currently conducting proof of concept studies which include cell isolation, processing and scale-up, product release and preclinical evaluation. Once these studies are successfully completed, the next steps will include GMP manufacturing of the cells and formal pre- clinical studies in preparation for human clinical trials.

New Cell Pouch(TM) Clinical Indications for Metabolic Disorders

As the Company continues its work on the diabetes and hemophilia indications, we are pursuing new autograft (self-cell) and/or allograft (donor-cell) clinical indications with academic and corporate collaborators to further expand the application of its cell therapy platform technologies. We plan to announce these further applications as new development agreements are signed.

Patent Developments

A strong patent portfolio covering the Company’s cell therapy technologies is an essential part of our business and an important element for attracting large pharma development partners. As such, we have put resources into developing our international patent portfolio and continue to be successful with the ongoing process of international patent prosecution involving the Company’s medical device, therapeutic cell and local immune protection technologies. We currently have achieved 25 issued patents and 27 pending patents in 9 patent families.

Development of Strategic Business Partnerships

As part of our partnering and licensing strategy, Sernova has hired a business development team with extensive experience with in-licensing technologies and developing corporate partnerships with emerging and large pharma/medical device companies. These activities broaden the company’s technology base, validate our technologies, and may provide additional funding sources and expertise to advance our clinical programs to product approval. In this regard, we are in business discussions with a number of companies with complementary technologies which we expect to result in collaborations to develop new products.

“With its GMP manufactured product, years of strong pre-clinical results and encouraging clinical safety, Sernova’s Cell Pouch(TM) is becoming recognized as an elegant delivery module. We are expanding our relationships with a number of therapeutic cell companies who have interest in their ‘therapeutic cell payload’ being paired with our technologies,” remarked Kevin Egan, Chair of Sernova’s business advisory board. “The pharmaceutical companies we are in discussions with see the Cell Pouch(TM) in conjunction with our local immune protected cell-based technologies as the total regenerative medicine package to treat serious chronic diseases.”

Grant Funding

The Company has applied for and continues to seek non-dilutive sources of funding in the form of government and non-profit society grants which can result in funding for the Company’s ongoing and new research and development programs to support our treasury. The Company has to date secured over $1.0 million in such grants.

Selected Highlighted Corporate Developments

Following are highlights of significant recent developments at Sernova:

• Released positive interim results from our human clinical trial of the Cell Pouch(TM) with insulin producing islets for the treatment of Type I diabetes, demonstrating tissue biocompatibility and safety for up to 6 months, as well as proof of 30 day islet survival within the Cell Pouch™ following islet transplant.

• Established an agreement with Medicyte GmbH and initiated pre-clinical studies to jointly evaluate the use of Medicyte’s upcyte® cells in Sernova’s Cell Pouch(TM) to treat patients with Hemophilia A disease.

• Received the first patent allowance for Methods and Devices for Cellular Transplantation from the Australian Patent Office and further allowances in additional jurisdictions.

• Continued evaluation of our local immune protection technology within the Cell Pouch(TM) for treatment of chronic diseases following receipt of a contribution agreement for up to $254,300 from the National Research Council of Canada for continued research and development.

• Appointed biopharma entrepreneur and investor Frank Holler to the Board of Directors.

• Established a world class business development team to establish corporate partners for Sernova’s programs and to expand Sernova’s proprietary technologies through academic and corporate partnerships.

“We are making solid progress on multiple fronts as we continue to develop our platform technologies in the regenerative medicine arena”, stated Dr. Philip Toleikis, Sernova’s President and CEO. “The further success in our international intellectual property patent development, pursuit of stem cell technologies to gain a virtually unlimited supply of cells to treat diabetes, expansion of our research and development programs into new disease indications, and expansion of our management team in business and corporate development all demonstrate our long-term commitment to develop our promising therapeutic cell technologies into products that markedly improve patient outcomes.”

Click here to view the full news release.

Ambu will be distributing Intronix Technologies' Innovative Myoguide™ System Worldwide

TORONTO, Oct. 27, 2014 /PRNewswire/ -- Ambu, a leading global supplier of medical devices, has signed a distribution agreement with Intronix Technologies. Intronix Technologies' innovative Myoguide EMG guided injection system will be available through Ambu's worldwide network of distributors, which already services Ambu's customers locally. The revolutionary Myoguide™ Needle EMG Guided Injection System has breakthrough technology that gives practitioners a superior way to deliver targeted injections. Myoguide™ uses the patient's muscle signals to provide ongoing visual and audio feedback, during the needle insertion, to help find focal areas responsible for pain and spasticity.

Developed by the Canadian-based innovator, Intronix Technologies Corp. (http://www.intronixtech.com), the Myoguide™ system detects critical information about the tissues targeted for injection. It then provides instant reporting that increases the odds for successful, accurately measured injections, thus helping minimize mistakes, inaccurate dosages and potential side effects.

Myoguide™ is most frequently used to help direct injections with Botox® and similar drugs. Myoguide™ uses an innovative signal display and high fidelity audio feedback to help clinicians find the optimal injection sites to help manage myofascial pain, spasticity, fibromyalgia, and even cosmetics injections.

"We are pleased to join forces with Ambu to provide our clinician customers with Ambu's Neuroline hypodermic needle electrodes and surface electrode product lines. This will present a complete clinical package for clinicians managing myofascial pain, movement disorders, spasticity and cosmetic applications," says Dr. Evan Friedman, President of Intronix Technologies. "Ambu has a great reputation of manufacturing and distributing excellent medical devices, and we are proud to be a part of the team. Ambu has a solid distribution network and will give Myoguide full exposure throughout Ambu's extensive worldwide healthcare community."

Intronix (booth 306) and Ambu USA (booth 404) will be at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly, November 13–16, 2014 at the San Diego Convention Center.

Click here to view the full news release.

Vasomune Therapeutics awarded $1.5 million to advance lead asset for renal disease

TORONTO (October 20, 2014) — Vasomune Therapeutics, a biotechnology start-up founded by Drs. Dan Dumont and Paul Van Slyke of Sunnybrook Research Institute (SRI) in partnership with MaRS Innovation, has received $1.5 million, in part through Genome Canada’s Genomic Applications Partnership Program (GAPP), to advance Vasculotide, the company’s lead Tie-2 activating agent, towards clinical development. The Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, announced the funding as part of 12 selected projects under Genome Canada’s Genomic Applications Partnership Program (GAPP), on October 15 in Wallenstein, Ontario.

“We believe that our technology is well positioned to accelerate from preclinical research into clinical development based on its strong data package,” said Parimal Nathwani, president and CEO of Vasomune Therapeutics. “This award, in combination with industry funding, validates the Vasculotide opportunity and gives us the required funds to advance the drug candidate toward the clinic.”

In preclinical studies, Vasculotide has shown to be an effective treatment for multiple renal diseases including acute kidney injury (AKI), which in humans is a possible outcome of kidney function loss that manifests in nearly a third of high-risk cardiac patients. AKI may result from short-term interruptions in blood flow during surgery; 11 percent of patients who develop AKI after bypass surgery will die. People who survive AKI are at risk of developing longer-term kidney complications such as chronic kidney disease or End Stage Renal Disease. Vasomune’s founders conceptualized and designed Vasculotide to bind to the Tie-2 receptor, which is responsible for maintaining vascular health (and thus blood flow).

With this new funding, a third from Vasomune and MaRS Innovation, a third from Genome Canada and a third from a leading multinational pharmaceutical company, Vasomune can transition its program into manufacturing optimization, pharmacokinetics and toxicology studies to prepare for clinical development in early 2016.

Specifically, the company seeks to understand how long Vasculotide circulates in the body, the length of time it activates the target Tie-2, how much of the drug can be given and the toxicology profile required for drug development and clinical trials.

“Translating this technology out of my academic lab and into development through Vasomune Therapeutics is extremely exciting,” says Dr. Daniel Dumont, senior scientist at Sunnybrook Research Institute and Canada Research Chair in Angiogenic and Lymphangiogenic Signalling. “We are pleased to be working with MaRS Innovation to bring Vasculotide to market.”

Click here to view the full news release.

Xagenic Appoints Timothy I. Still as President & Chief Executive Officer

Toronto, ON (October 16, 2014) – Xagenic, a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, today announced the appointment of Timothy I. Still as President and Chief Executive Officer. Mr. Still will also serve as a member of Xagenic Inc.’s board of directors. Most recently, Mr. Still served as President and CEO of Accumetrics Inc., where over a period of five years he transformed the company into a commercially successful point-of-care test manufacturer which was ultimately sold to ITC in 2013. Prior to his time with Accumetrics, Mr. Still was Executive Vice President and Chief Commercial Officer at Hemosense, a point-of-care company that developed, manufactured and commercialized a handheld CLIA Waived device. Hemosense was acquired by Inverness Medical (now Alere) in 2007. Previously, he was Vice President of Sales and Marketing at Cholestech, and also held commercial positions at Boehringer Mannheim and Bio-Rad Laboratories.

“Xagenic’s X1™ molecular testing platform has the potential to revolutionize clinical diagnostics and to dramatically improve patient care by enabling immediate, accurate testing at the point of care,” said Timothy Still, CEO of Xagenic. “I am pleased to join the talented team at Xagenic and lead the company through the successful completion of clinical studies for this innovative diagnostic platform, and commercial launch in the U.S. and international markets.”

"We are extremely pleased to be able to install an executive with such an extensive background in commercializing new point-of-care diagnostic devices," said Jesse Treu, Board member and Partner at Domain Associates. "Tim’s experience in building commercially-viable companies in the diagnostics industry will be invaluable as Xagenic launches their lead product and continues to build menu for their platform. We are excited to have Tim on board as the company advances towards commercialization of the X1 platform."

Treu continued, “On behalf of Xagenic’s Board of Directors, I would like to thank Bruce Cohen for his contributions and service as Executive Chairman.” In conjunction with Timothy Still’s appointment, Bruce Cohen has stepped down from his position on the company's board.

About Xagenic

Based in Toronto, with an office in San Francisco, Xagenic is a privately held molecular diagnostics company developing a fully-automated molecular diagnostic platform that will enable lab-free testing with a time-to-result of 20 minutes. The company is developing a menu of infectious disease tests that will have a positive impact on patient care and reduce health care costs. The company is supported by private investors, including Domain Associates, CTI Life Sciences Fund, the Ontario Capital Growth Corporation and BDC Capital. Xagenic recently received the Frost & Sullivan 2014 Point-of-Care Diagnostics New Product Innovation Leadership Award. For more information, please visit http://www.xagenic.com.

For more information, contact:

Shana Kelley, Ph.D. Founder & Chief Technology Officer shana.kelley@xagenic.com 1 (416) 363-1999 x300

Timothy I. Still President & Chief Executive Officer timothy.still@xagenic.com 1 (416) 363-1999 x250

Click here to view the full news release.

Xagenic Announces $6 Million Genome Canada Funded Project in Partnership with University of Toronto

Toronto, ON (October 15, 2014) – Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, announced today that its project in partnership with the University of Toronto was successful in securing funding from Genome Canada under the Genomic Applications Partnership Program (GAPP). The project titled “Development of Low Cost Testing Chip and Device for Hepatitis C Testing” was approved with funding up to a maximum of $5,999,865 over three years. The Ontario Ministry of Research and Innovation is supporting the project with a grant matching the Genome Canada contribution.

“This is a tremendous opportunity for us to leverage the viral assay development and electrochemical detection expertise in the labs of Dr. Shana Kelley and Dr. Edward Sargent at the University of Toronto to significantly advance our own research programs on several fronts,” commented Dr. Graham D. Jack, Senior Director of Research and Development at Xagenic. “Under this joint program, we anticipate development of a new lower-cost substrate chip, which will significantly bring down the total cost of our in-cartridge AuRA™ detection technology.

Dr. Jack continued, “We are also looking forward to the development of a new hepatitis C virus genotyping assay, which will be useful in managing HCV patients by guiding therapy decisions. Diagnostic testing for HCV has been suboptimal to date as screening has relied on antibody-based tests with poor sensitivity. Any positive test results need to be confirmed using nucleic acid based methods, assuming reference lab testing is available. This new assay on the Xagenic platform will make rapid front-line nucleic acid testing for HCV possible in any clinical setting.”

“We are pleased to be a part of this Genome Canada funded project, as the outputs will help us with our long-term objectives of lowering our cost of goods sold, building out our menu of infectious disease tests and adapting our detection technology to address the needs of additional market segments,” added Ihor Boszko, Xagenic’s Vice President of Business Development. “We expect the project will generate novel intellectual property that will provide Xagenic with a greater competitive advantage in the diagnostic testing market.”

According to the World Health Organization, 130-150 million people globally are infected with the hepatitis C virus, with approximately 500,000 people dying each year from the resultant liver disease. Nearly 80% of infected people do not exhibit symptoms and as a result, early diagnosis is rare. For those who go on to develop chronic HCV infection, diagnosis often occurs after serious liver damage has developed. Early detection through molecular screening of increased risk populations can prevent both complications and transmission of the virus. Because treatment response is genotype-dependent, determining the virus genotype(s) is important to guide treatment decisions and management of the disease.

About Xagenic Inc. Based in Toronto, Ontario, Xagenic is a privately held molecular diagnostics company developing a fully-automated molecular diagnostic platform that will enable lab-free testing with a time-to-result of 20 minutes. The company is developing a menu of infectious disease tests that will have a positive impact on patient care and reduce health care costs. The company is supported by private investors, including Domain Associates, CTI Life Sciences Fund, the Ontario Capital Growth Corporation and BDC Capital. Xagenic recently received the Frost & Sullivan 2014 Point-of-Care Diagnostics New Product Innovation Leadership Award. For more information, please visit http://www.xagenic.com.

For more information, contact:

Xagenic Inc. Ihor Boszko Vice President, Business Development ihor.boszko@xagenic.com 1 (416) 363-1999 x500

Click here to view the full news release.

Theralase Partners with SAFC in Manufacture of Anti-Cancer Drugs

Toronto, Ontario – October 7, 2014 –Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) announced today that it has collaborated with Sigma-Aldrich Corporation’s (NASDAQ: SIAL) custom manufacturing services business unit SAFC® Commercial , in the manufacture of the Photo Dynamic Compounds (“PDCs”) being developed by Theralase for the destruction of cancer. Under the terms of the agreement, SAFC will develop the Standard Operating Procedures (“SOPs”) to manufacture initial quantities of each of Theralase’s four lead PDCs. Once Theralase selects the final lead PDC at the end of the fourth quarter 2014, SAFC will manufacture both a 100-gram pre-Good Manufacturing Practice (“pre-GMP”) batch and finally a 500-gram GMP batch of the PDC. This final 500-gram batch is intended to be suitable for final sterilization and packaging into individual patient doses for safety and efficacy evaluation through a Health Canada / FDA Phase I/IIa clinical trial, expected in early 2015.

SAFC is Theralase’s partner of choice to provide a continuous supply of the lead PDC for future clinical trials and eventually commercialization of the PDC for human bladder cancer applications.

Roger Dumoulin-White, President and CEO of Theralase Inc. stated that, “Theralase is delighted that we have partnered with SAFC in the development and manufacture of our PDCs, as they have the depth and experience to execute on the manufacture of our PDCs, quickly, efficiently and in whatever quantity is required. SAFC brings a very sophisticated and experienced team of analytical and developmental chemists to the table, whose expertise will prove indispensable in the development and commercialization of our anti-cancer technology.”

Dr. Arkady Mandel, Chief Scientific Officer of Theralase Inc. stated that, “SAFC has been selected as our chosen partner in the development of our PDC platform because of their manufacturing expertise. I was extremely impressed with the knowledge and experience that their team brings to the development of our PDCs.”

Click here to view the full news release.

Proteocyte Diagnostics Highest Ranked Life Sciences Company in NACO’s Most Promising Canadian Startup of the Year Competition

QUEBEC CITY – Proteocyte Diagnostics Inc., a company with a unique test for early identification of oral cancers, was the highest ranked life science startup in the Most Promising Canadian Startup of the Year competition, and overall runner up, held by the National Angel Capital Organization (NACO) last night. Proteocyte Diagnostics is a Canadian molecular diagnostics company that has developed a novel diagnostics test, Straticyte™ that objectively and accurately detects precancerous oral lesions at high risk of becoming cancerous. Straticyte is the first and only molecular diagnostic test for oral precancerous lesions that provides an objective and accurate prediction score as evidenced by retrospective clinical studies.

“We were pleased to be the highest ranked life science startup,” said Dr. Mario Thomas, President of Proteocyte Diagnostics. “It was a great opportunity to tell our story to over 200 investors and be recognized with such a high ranking. This is another validation of Straticyte and the impact it will have by saving lives, increasing quality of life, reducing healthcare costs and providing a strong financial return.”

Dr. Sunny Kumar, Senior Commercialization Manager at Ontario Centres of Excellence (OCE) said, ”Clearly, Proteocyte is a top startup company in the Canadian landscape. This is why OCE sponsored Proteocyte Diagnostics as a candidate for Canada’s most promising start-up. Over the last two years, OCE has supported this top venture with its various programs including a recent investment of $250,000.”

NACO is a non-profit organization that promotes and helps create a vibrant Angel community in Canada. NACO’s annual Pitch Competition celebrates dynamic early-stage companies that have demonstrated successful growth and whose outstanding achievements have made them some of Canada’s most promising startups. Up to 15 semi-finalists were invited to attend the 2014 National Angel Summit and five (5) finalists, including Proteocyte Diagnostics, pitched on stage to over 200 Angel investors, venture capitalists and industry leaders. Most Promising Startup of the Year was selected by an expert panel of judges and audience voting and presented by KPMG Enterprise. The 2014 Pitch Competition was in Quebec City, on Thursday, October 2, during the 2014 National Angel Summit (October 1-3).

Click here to view the full news release.

Rna Diagnostics Awarded Patent for Test that Guides Cancer Chemotherapy

TORONTO, Ontario – Rna Diagnostics Inc., a Canadian company with unique technology for cancer chemotherapy management, was awarded a broad patent for RNA Disruption Assay™ (RDA) in Australia for “Method of using Tumour RNA Integrity to Measure Response to Chemotherapy in Cancer Patients,” #2008295394. “RDA™ is a significant advancement in cancer chemotherapy practice management. RDA assists clinicians in personalized treatment decisions and saves healthcare systems significant costs while improving outcomes for breast cancer patients,” said Dr. Ken Pritzker, President and CEO of Rna Diagnostics Inc.

Rna Diagnostics is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management. The company’s first product, RDA, determines early in a woman’s breast cancer treatment how she is responding to chemotherapy. Rna Diagnostics currently has ongoing clinical trials and collaborations with healthcare leaders in Germany, Italy, Sweden, United States, United Kingdom and Canada.

The patent allowance in Australia is an important advance in protecting the innovative technology and commercial potential of Rna Diagnostics. Rna Diagnostics has additional patents pending globally and continues to expand its intellectual property portfolio.

Click here to view the full news release.

AvidBiologics Closes New Financing Round

TORONTO (Sept. 29, 2014) — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC). Led by Lumira Capital, the financing round included MaRS Investment Accelerator Fund (IAF), MaRS Innovation (MI), Rosseau Asset Management, and the company’s founding investors. Today’s financing builds on prior support from the Ontario Centres of Excellence (OCE), the National Research Council of Canada’s Industrial Research Assistance Program (NRC-IRAP), Ontario Ministry of Research and Innovation’s Business Accelerator Program (MRI-BAP) and other Canadian life science development organizations.

Click here to view the full news release.

AbCelex Technologies Inc. Secures an Additional $1 Million in Series A Financing

TORONTO, ONTARIO, Sept 15, 2014 – AbCelex Technologies Inc., a privately-held biotechnology company, committed to the discovery and development of innovative solutions to advance the health of food animals and human food safety, today announced it has closed an additional $1M in Series A venture capital financing. The financing was provided by Pinetree Capital Corporation and a private investor. The funds will be used to fund continuing research and development of the company’s antibody based approach to control a number of pathogens in farm animals implicated in a variety of food-borne illnesses. The Company anticipates that its advanced antibody screening and expression platform will address multiple pathogens in food animals. Currently there are no cost-effective, at source methods to control Campylobacter and Salmonella in poultry. AbCelex believes its solutions will offer an alternative to the use of antibiotics as a growth promoter in farm animals. In the U.S. the Centers for Disease Control and Prevention (CDC) estimates that 25% of reported cases of Campylobacteriosis and up to 8% of Salmonellosis cases are antibiotic resistant1.

“This is an exciting time to become involved with AbCelex. The Company’s disruptive technology has the potential to dramatically improve food animal health and quality of food for the world’s population” said Mathew Wilson, Vice President at Pinetree Capital. “In the poultry industry alone, with over forty billion broilers harvested each year, AbCelex’s anti-microbial feed additives have huge market potential.”

“With financial support from Pinetree, we’ll be able to accelerate our pipeline of R&D programs and strengthen our intellectual property position”, said Dr. Babaei, President & CEO of AbCelex. “We’ll continue to build on our revolutionary antibody engineering techniques, advance our protein expression systems and complete our initial field trials by the end of this year”.

Previously, AbCelex Technologies Inc. secured $2M in Series A financing from Cultivian Sandbox Ventures, LP, a Chicago based agriculture and biotech fund.

Click here to view the full news release.

Entrepreneur redevelops one of life’s scariest tests

NOMINEE JESSICA CHING When Jessica Ching studied industrial design at OCAD University in Toronto, she didn’t think she would end up as a health-care entrepreneur.

“It’s probably not the conventional path. But I was interested in the intersection between design and health care,” she says.

Ms. Ching is co-founder (with Evan Moses) and chief executive officer of Eve Medical Inc., a Toronto startup that has developed a product called HerSwab for women to test themselves for cervical cancer.

“This project actually started as my thesis research project at OCAD University. I had a conversation with a group of women, and the topic of cervical cancer screening came up while we were just chatting,” Ms. Ching says.

“One of the women I was speaking with said that she knew that cervical cancer screening was important to her health. But she found the test and the process made her so uncomfortable that she had actually avoided being tested for the last five years.”

This intrigued Ms. Ching. “A lot of the other women around the table agreed that it was an awful experience. I thought, isn’t it quite tragic that these women are not taking care of themselves, just because the experience is uncomfortable.”

Ms. Ching and Ms. Moses looked at what was preventing women from being tested and discovered that the main barrier was a reluctance to go to a clinic.

“Women say they don’t have time, can’t get to a family doctor, can’t get daycare or transport. So we make the first step really easy. They can screen themselves, and if they have a positive result then they can take it to a clinic.”

Eve Medical’s trademarked HerSwab, available now only for research and limited commercial use, is designed to enable women to collect samples themselves near the cervix, where strains of high-risk human papillomavirus (HPV) are more likely to be found.

The technology is being developed to make sample collection and shipment to the doctor’s office as foolproof as possible, and to point women toward seeking appropriate follow-up care if their self-testing shows up positive.

“There’s a lot of opportunity in health care to redesign things to be more useful for people, in ways that would increase compliance,” she says.

With financial help from friends, family, early-stage angel investors and funding from the Ontario Centres of Excellence’s Martin Walmsley Fellowship, the company, now four people, including Ms. Ching, was started in 2010, a year after she graduated from OCAD University.

“Right now we’re raising our first real equity round. Fundraising can certainly be challenging for first-time entrepreneurs, and I have had to learn on the fly,” she says.

The company has been meeting prospective investors through groups such as the not-for-profit Ontario Bioscience Innovation Organization, the MaRS Centre, business and female entrepreneur networks such as SheEO, Springboard and Next Founders. “I also reach out to investors that have some alignment with Eve Medical, or through introductions from other health-care companies,” Ms. Ching says.

While she has no personal or family experience with cervical cancer, Ms. Ching says prevention matters a lot to her. Cervical cancer claims more than 275,000 lives each year, mostly among women who do not undergo screening. Among those who do, “30 per cent are not screening according to guidelines,” she adds.

“It’s not a technical problem, it’s a behaviour problem. And that’s where design comes in. The designer will look not at whether something functions or not, but whether it functions for people.”

Once the design process is under way, one of the biggest learning curves for an entrepreneur such as Ms. Ching is to find out exactly how to be one.

“I don’t think there’s a way to train, other than to be one. There are skills that you could work on improving to give yourself a leg up before you start a business, but if you try to improve them all upfront, you’ll never get started. The challenge and beauty of running a startup is that you have the opportunity to learn it all at once,” she says.

“Starting a company is the hardest thing I’ve ever done, but I’m glad I did. Having a great team is really critical. One thing I’ve learned is that it’s practically impossible to over-communicate, but easy to under-communicate. Taking time to speak openly about how we can improve has been very important. We also receive a lot of guidance from our advisers and mentors,” Ms. Ching adds.

She recommends applying principles called “objectives and key results,” which she and her team have reviewed through a video produced by Google Ventures. The system helps her small team stay aligned and accountable to each other.

“I have also met women who have experienced cervical cancer and have encouraged me. If we can prevent even one woman from developing cervical cancer, I would feel that we’ve made a difference.”

Click here to view the full article.

Armour Therapeutics discovers synergies between prostate cancer treatment and conventional chemotherapy to treat aggressive tumours

Armour’s anti-hormonal therapy, AT-001, could help improve survival rates in prostate cancer Toronto, May 13, 2014 – Biopharma company Armour Therapeutics has published exciting new findings for the treatment of hormone refractory prostate cancer.

Data from animal studies show that combination therapy of docetaxel, the current standard-of-care chemotherapy for the management of advanced prostate cancer, along with Armour’s AT-001, inhibited androgen-independent prostate tumor growth by up to 98% compared to controls. “Conceivably, combination therapy with AT-001 could enable lowering docetaxel dosing regimens in the clinic, thereby reducing the concomitant toxicity associated with chemotherapy”, says Dr. Anton Neschadim, Director of Drug Development at Armour Therapeutics and lead author on the study.

“Combination treatment of Armour’s AT-001 with docetaxel may either allow for using less docetaxel or enable a longer treatment cycle to achieve the same efficacy and lower side-effects and toxicity” said Dr. John Trachtenberg, Director of the Prostate Cancer Centre at the Princess Margaret Hospital in Toronto, and a co-author on the study.

Armour is developing a first-in-class anti-hormonal drug for the treatment of advanced prostate cancer, which occurs once tumors have become resistant to conventional drugs that are designed to block the action of androgen hormones. In preclinical studies, Armour’s lead compound, AT-001, has been shown to impair human prostate tumour growth, making it an alternative candidate course of treatment once patients have exhausted their options with the current leading anti-hormonal therapies on the market.

“AT-001 is a relaxin receptor antagonist designed to maintain an anti-androgen effect in patients developing resistance to currently marketed anti-hormonals. In addition, by blocking the relaxin hormone pathway, it may reduce tumour growth, impair angiogenesis, constrict tumoral blood flow, and reduce the risk of metastasis,” says Dr. Josh Silvertown, CEO and Founder of Armour Therapeutics Inc, and senior author on the study.

The study entitled, “Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts” was published in Endocrine-Related Cancer, the premier global journal for covering all aspects of basic, translational and clinical research on hormones and cancer. An abstract of the paper can be found here: http://dx.doi.org/10.1530/ERC-14-0088.

Click here to view the full news release online.

AbCelex Technologies Secures Two Million in Series A Financing

TORONTO, ONTARIO, April 28, 2014 – AbCelex Technologies Inc., a privately-held Canadian biotechnology company committed to the discovery and development of innovative solutions to advance the health of food animals and human food safety, announced today it has closed on $2.0 million in Series A venture capital financing. The round was led by Cultivian Sandbox Ventures, LP, a Chicago-based fund with substantial expertise in agriculture and industrial biotechnology sectors. The funds will support research and development of the company’s antibody-based approach to control pathogens in farm animals related to food-borne illnesses. With a growing world population, human food safety remains a pressing challenge. The Centers for Disease Control and Prevention in the U.S. report that in the U.S. about 1 in 6, or 48 million, people get sick each year from contaminated food with 128,000 hospitalizations and 3,000 deaths annually. Increasing health concerns over microbial resistance to antibiotics is driving government regulators to encourage alternatives to the regular use of antibiotics in farm animals.

AbCelex Technologies is pleased to welcome Ron Meeusen, Matthew Bell, and Paul Dick to the Company’s Board of Directors.

Ron Meeusen, PhD

Dr. Meeusen is a Managing Director of Cultivian Sandbox and co-founder and Managing Partner of Cultivian Ventures. Ron has over 30 years of experience in bringing new technologies and products to market. He has led research and development for major corporations in agricultural chemicals, field crop and vegetable genetics and breeding, animal health, novel foods and industrial materials. Ron has been a frequent speaker at conferences, a consultant to Federal policy on biotechnology regulatory issues, and active in industry trade groups. Prior to forming Cultivian Ron led the expansion of the biotechnology research and development program of Dow AgroSciences, and founded a successful biopharmaceutical company, Immuneworks, Inc. Ron represents Cultivian on the board of directors of Allylix, Proterro and Rivertop Renewables, and represents Cultivian Sandbox on the board of EnEvolv. He was also a member of the boards of directors of Divergence, Inc., which was sold to Monsanto Company in February of 2011, and of Aratana Therapeutics, which went public in 2013. Ron holds a Ph.D. from the University of California, Berkeley in plant cell biology.

Matthew Bell

Mr. Bell is a Principal of Cultivian Sandbox. Matt has over 9 years of technology commercialization and startup experience through his time with the University of Michigan’s Office of Technology Transfer where he was directly involved with the formation activities of over 20 startup companies. Prior to working at the University, Matt spent over 10 years in the Agriculture industry working for several production Ag supply companies including Growmark Incorporated where he was involved with their highly regarded precision farming services group. Matt has two degrees from the University of Illinois in Agronomy and a Masters of Business Administration and spent much of his early career as a professional grain farmer on the family farm that he grew up on in Central Illinois.

Paul Dick, DVM, MSc

Dr. Dick has 25 years of experience in the animal health industry including product development, regulatory affairs, business development, commercialization and general management. Roles in this sector have involved both large and medium multinationals and small start-up companies, in various capacities including COO of Naturagen Health Solutions within Elanco and CEO of Chemaphor involved in development of pharmaceuticals and veterinary natural health products. Dr. Dick has worked extensively with Health Canada’s Veterinary Drugs Directorate and the Canadian Food Inspection Agency on numerous regulatory submissions and on departmental committees. He has served a number of organizations including as Director of the Canadian Animal Health Institute, President of the Ontario Veterinary Medical Association, and peer reviewer of NSERC strategic grants. He holds a veterinary degree with advanced training in infectious diseases and immunology.

“Backed by Cultivian Sandbox Ventures, we are well on our way to developing our lead anti-Campylobacter product for poultry. AbCelex’s antibody-based approach to controlling harmful pathogens is poised to have a dramatic impact on human food safety”, said Dr. Babaei, President & CEO of AbCelex Technologies. “Our innovative intellectual property platform combined with our proprietary genomics know-how allows us to deliver unique antimicrobial solutions against various pathogens in multiple farm animal species.”

“AbCelex has some exciting next-generation biotechnology to address some of the world’s pressing food safety challenges”, said Dr. Meeusen of Cultivian Sandbox. “The team at AbCelex has overcome the difficulties in delivering antimicrobial antibodies through oral administration to farm animals. Their feed additive approach will revolutionize the treatment of many food-borne pathogens improving food safety for all of mankind.”

About Cultivian Sandbox Ventures

Cultivian Sandbox is a venture capital firm focused on building next-generation disruptive agriculture and food technology companies capable of generating superior returns. As both experienced operating managers and venture investors we add value to portfolio companies both through our highly skilled team and extensive industry network. Our expertise in sourcing, evaluating, closing, managing and ultimately exiting successful equity investments positions us not only to build stronger businesses, but reshape industries. Additional information can be found at: http://www.cultiviansbx.com.

About AbCelex Technologies Inc.

AbCelex Technologies Inc., is a privately-held Canadian biotechnology company committed to the discovery and development of innovative solutions to advance the health of food animals and improve human food safety. Employing advanced genetics and bioengineering techniques, AbCelex’s antibody based approach delivers antimicrobial solutions against various pathogens in several food animal species implicated in food-borne illnesses. For more information, visit http://www.abcelex.com.

For further information, please contact:

Saeid Babaei (647) 494-8787; ir@abcelex.com

Click here to view the full news release online.

Kevin Egan Joins Sernova as Chair Business Advisory Board

Experienced Biotechnology Executive and Investor to Contribute Strategic Business Development Expertise to Sernova Source: Sernova Corp FOR RELEASE May 12th, 2014, 6:00 a.m. EDT

LONDON, ONTARIO--(Marketwire – May 12th, 2014) - Sernova Corp. (TSX-V: SVA) is pleased to announce that Mr. Kevin M. Egan, President, Borealis Biotechnology LLC, an international biotechnology consulting company, has joined Sernova as Chair of the Business Advisory Board. A Washington-based entrepreneur and investor, Mr. Egan is one of North America’s most prolific, biotech entrepreneurs, bringing over 25 years of success-driven experience in biopharma, and commercialization & partnering expertise to Sernova. He has been directly involved in helping to develop blockbuster drugs from two, bell-weather US biotech giants: Amgen and Icos.

“We are elated to have a seasoned biotech business development colleague join Sernova at this exciting juncture”, remarked Dr. Philip Toleikis, President & CEO. “In addition to Cialis, Mr. Egan worked on two Amgen blockbuster drugs – Epogen, also known as Erythropoietin, which is a red blood cell hormone used primarily for treating people with anemia caused by a variety of diseases; and Neupogen – also known as GCSF, which is a white blood cell growth factor used extensively during chemotherapy. These biopharmaceuticals, along with their derivatives, are among the biggest selling pharmaceuticals of all time”, added Dr. Toleikis.

"I am pleased to be joining Sernova at a time when pharma is looking for disruptive technologies to bolster their pipelines," said Mr. Egan. "I am looking forward to working with Dr. Toleikis, and the industry-recognized team he has assembled, to advance Sernova's therapeutic cell-based product development programs and drive value for shareholders."

Mr. Egan began his career at Amgen, Inc. where he worked in research for ten years. In addition to negotiating licensing, partnering, and outsourcing agreements for both biologics and small molecules he was responsible for building and running ICOS’ biologics manufacturing business including marketing, business development, and managing the P&L. Over the course of his career, Mr. Egan has negotiated and closed over 100 contracts and agreements with companies from the U.S., Canada, Europe, Australia, Israel, Japan and Taiwan. To date he has brought in over $150M in revenue for various contract manufacturing organizations.

Mr. Egan has an MBA from the University of Washington, a Master’s degree in Biochemistry and Molecular Biology from U.C. Santa Barbara, and undergraduate degrees in Biology and Chemistry from U.C. Santa Cruz.

Click here to view the full news release online.

Interface Biologics Appoints Dion Madsen to Board of Directors

Toronto, ON, Canada, May 12, 2014 -- Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Dion Madsen to the Board of Directors. Mr. Madsen is a Senior Managing Partner in the Healthcare Fund at BDC Venture Capital. In this role, he is responsible for overseeing the Healthcare Fund investments and maximizing value creation across the portfolio. Mr. Madsen brings over 15 years of senior management experience as a financial executive and venture investor, most recently as Founder and Managing Director of Physic Ventures, and as Managing Director of Unilever Technology Ventures, where he led the completion of the investing cycle for Unilever’s North American Corporate Venture activity. Prior to Unilever, Mr. Madsen led Chiron Corporation’s investor communications, as Director of Investor Relations, and worked in corporate development, building a new strategy for the company’s $500M BioPharma business. Before moving to San Francisco, Dion spent five years as Partner of RBC Capital Partners’ Life Sciences Venture Fund, the first third-party capital fund in RBC Capital Partners’ history.

“BDC has been an active investor in Interface Biologics since 2004 and the Company continues to be one of our top portfolio companies”, commented Mr. Madsen. “As I’ve started to get more actively involved with the Company, I’m even more impressed with the technology platforms, the commercial success to date and the future prospects. I want to thank Denis Ho for representing BDC on the IBI Board prior to his retirement and his significant contributions. I look forward to working with the management team as a Board member.”

“We are very pleased to have Dion join our Board of Directors", stated Tom Reeves, President and CEO, Interface Biologics. “His deep experience in life sciences venture capital coupled with his understanding of the corporate venture capital and M&A markets will be an invaluable resource for IBI. He’ll be a great addition to our Board. I would also like to thank Denis Ho for his years of support as an IBI Board Member – he has been a big part of our success to date and we will continue to benefit from his guidance and mentorship well into the future."

Click here to view the full news release online.

Sernova Announces Appointment of Nick Borrelly to Corporate Development Role

Seasoned biopharma executive brings corporate development expertise to Sernova LONDON, ONTARIO--(Marketwired - May 7, 2014) - Sernova Corp. (TSX VENTURE:SVA) is pleased to announce that Mr. Nick Borrelly is joining Sernova in a consultant corporate development role. Mr. Borrelly has over 25 years' experience in corporate/business development as well as marketing and sales in the pharmaceutical (Ciba-Geigy, Novartis and Sanofi-Aventis) and biopharma industries. As President of Camargue Consulting, he specializes in development, evaluation and in-licensing of technologies, initiation of strategic alliances with multi-national corporate partners, and leading sales and marketing teams for commercial stage products.

"Nick's extensive corporate development network and partnering expertise will be invaluable to creating significant shareholder value through attracting strong commercialization partners for our products. As Sernova is now exploring additional clinical applications of the Cell Pouch™, establishing corporate partners to help accelerate development has become an important part of our corporate strategy forward", stated Dr. Philip Toleikis, Sernova's President and CEO.

Mr. Borrelly said, "I am excited to work with Sernova's CEO, Dr. Philip Toleikis, and his team to fully implement the strategic vision for its disruptive technologies for the cell-based treatment of chronic diseases."

Nick's past roles include Manager, Business Development - Licensing & Acquisitions with Sanofi Aventis Pharma Canada; Vice President, Business Development for MNLpharma (U.K.) Ltd.; and Vice President, Business Development for CV Technologies/Afexa Life Sciences Inc. As a Director with Nucleus BioScience Inc., he coordinated its amalgamation with Stratos BioSciences Inc. and Brightwave Technologies Inc. to create SNB Capital Corp., which subsequently took the biotherapeutics company Protox Therapeutics Inc. (now Sophiris Bio Inc) public in 2004. Nick is currently a member of the Board of Directors of Eternity Healthcare, and Auxellence Health Corporation.

Click here to view the full news release online.

Sernova’s Cell Pouch™ Diabetes Clinical Trial Demonstrates Interim Safety and Biocompatibility

Sernova’s Cell Pouch with insulin-producing islets is safe and biocompatible in patients with unstable diabetes Source: Sernova Corp FOR RELEASE April 22nd, 2014, 6:00 a.m. EDT LONDON, ONTARIO--(Marketwire – April 22nd, 2014) - Sernova Corp. (TSX-V: SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, today announced interim results in an ongoing type 1 diabetes human clinical trial with the Company’s Cell Pouch(TM).

Sernova’s human clinical trial is designed to assess the safety and efficacy of the Cell Pouch in subjects with unstable diabetes receiving an islet transplant. Interim study results in the first group of patients support that the implanted Cell Pouch, transplanted with insulin-producing islets is showing longer-term safety and biocompatibility with one of the patients beyond the 180 day time point.

Encouraging early results up to 30 days post-islet transplant were presented at the International Pancreas and Islet Transplantation Congress in September, 2013. These results showed after implantation under the skin, the Cell Pouch is safe and biocompatible. Following islet transplantation, the islets living within a natural tissue matrix were supported with a rich supply of blood vessels, similar to the pancreas. Of further importance, the islets were shown to make insulin, somatostatin and glucagon – key hormones in the control of blood sugar levels. The ongoing study is being conducted with Dr. James Shapiro as principal investigator at the University of Alberta Health Sciences Centre in Edmonton, Alberta.

"The fact that the Cell Pouch continues to exhibit both safety and biocompatibility in longer term follow-up is an important milestone in the early clinical testing of this device, and provides encouragement that human islets transplanted within the device may provide the opportunity to change the standard of care of patients with diabetes," said Dr. James Shapiro. “I look forward to the ongoing results of the investigation as the study progresses."

The study, entitled “A Phase I/II Study of the Safety and Efficacy of Sernova's Cell Pouch for Therapeutic Islet Transplantation,” is an open label, non- randomized, Phase I/II safety and efficacy study of up to 20 patients with type 1 diabetes undergoing allograft pancreatic islet transplantation. Patients who have met the enrolment criteria and provided informed consent are implanted with the Cell Pouch approximately 2-24 weeks prior to transplantation of donor human islets. To prevent islet graft rejection, the standard of care immunosuppressive regimen is provided.

The primary endpoint of the study is to assess the safety of the Sernova Cell Pouch in these patients just prior to islet transplantation, following islet transplantation and at various points during follow up. The secondary endpoint of the study, efficacy, is to determine the proportion of subjects implanted with the Cell Pouch and transplanted with islets who achieve and maintain insulin independence. Patient follow up occurs for a minimum of three years to assess long-term safety and efficacy.

“In the second half of 2014, we expect to provide further preliminary safety and efficacy data”, remarked Dr. James Shapiro.

"This interim update by Dr. Shapiro suggests we are making positive strides forward. The Cell Pouch could potentially be a game changer for patients suffering from this debilitating disease. Indeed, this is the result of years of hard work and dedication from our company's staff and collaborators," said Dr. Philip Toleikis, President and CEO of Sernova Corp. "We have developed the subcutaneous Cell Pouch for Sernova's first clinical application, insulin- dependent diabetes, as an alternative site for islet transplantation that may allow for safer, more efficient engraftment of islets and potential improved long-term insulin independence using a marginal islet mass. What adds further credence to the Cell Pouch’s mechanism of action is the application of the Cell Pouch for other clinical indications which Sernova is undertaking”, added Dr. Toleikis."

Click here to view the full news release online.

Spectral Updates Status Of EUPHRATES Trial

-Trial to continue with a total of 650 patients- TORONTO, April 14, 2014 - Spectral Diagnostics Inc. (TSX:SDI) (OTCQX: DIAGF) ("Spectral" or the "Company"), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that the Data Safety Monitoring Board (DSMB) for the EUPHRATES trial has completed its review of the detailed analysis it had previously requested.

Based on the current recommendations of the DSMB, the sample size has been recalculated and increased from 360 to 650 patients.

This increase in the number of enrolled patients enhances the likelihood of demonstrating, with sufficient power, a statistically and clinically significant effect. The revised sample size falls within the statistical plan already agreed to by the United States Food and Drug Administration (FDA). Spectral will also promptly submit a protocol amendment to the FDA, as recommended by the DSMB, for an additional exclusion criterion.

The EUPHRATES trial has continued to enrol patients and, as of April 11, 2014, 271 patients have been randomized.

"We are pleased with the positive outcome of the second interim analysis," said Dr. Paul Walker, President and CEO of Spectral. "The enthusiasm and support from our clinical trial sites has been outstanding. Based on current enrolment rates and number of sites, we anticipate completion of the trial in the first half of 2016."

Click here to view the full news release online.

Profound Medical Announces Closing of Enrollment Into TULSA Clinical Trial for Treatment of Localized Prostate Cancer

Profound Medical has closed enrollment of its multi-centre TULSA clinical trial to evaluate the safety and feasibility of the Profound Medical device in patients with localized prostate cancer. Enrolled patients will be followed for 12 months following the treatment. Toronto, Ontario Canada (PRWEB) April 11, 2014

Profound Medical Inc. today announced it has closed enrollment of its TULSA (Transurethral ULtraSound Ablation) Clinical Trial with 30 patients enrolled. The TULSA Clinical Trial is a Phase I, multi-centered study designed to evaluate the safety and feasibility of the Profound Medical device in patients with localized prostate cancer. Enrolled patients will be followed for 12 months following the treatment.

The device offers the prospect of significantly improved clinical outcomes, and a marked departure from current methods, by virtue of its ability to treat the whole gland in one session, with the potential for unprecedented accuracy and minimal side effects.

Combining the use of thermal ultrasound therapy with real-time MR Image guidance, the Profound system operates within an MRI suite, and offers clinicians and patients a precisely targeted treatment using a minimally invasive, trans-urethral approach. The Profound treatment is completed in a single session and enables the patient to return home after a short outpatient recovery period.

“The successful enrollment for this trial represents another milestone for the company. We are grateful for the support and dedication of our clinical partners as we move to the next step to commercializing this technology,” states Steven Plymale, CEO at Profound Medical.

Click here to view the full news release online.